A novel mTOR inhibitor is efficacious in a murine model of colitis
Authors:
- Ravindra D. GupteRGRavindra D. Gupte
- Shruta D. DadarkarSDShruta D. Dadarkar
- Mahesh G. JadhavMJMahesh G. Jadhav
- Aditi A. TannuATAditi A. Tannu
- Pooja BhattPBPooja Bhatt
- Dimple R. BhatiaDBDimple R. Bhatia
- Nikesh K. DesaiNDNikesh K. Desai
- Vijaykumar DeoreVDVijaykumar Deore
- Nilambari YewalkarNYNilambari Yewalkar
- Ram A. VishwakarmaRVRam A. Vishwakarma
- Somesh SharmaSSSomesh Sharma
Open Access
- 1 December 2008
- journal article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 295 (6) , G1237-G1245
Abstract
Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T cell activation, increased production of proinflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium. Several compounds that possess antiproliferative properties and/or inhibit cytokine production exhibit a therapeutic effect in murine models of colitis. Mammalian target of rapamycin (mTOR), a protein kinase regulating cell proliferation, is implicated in colon carcinogenesis. In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a mTOR inhibitor and is efficacious in a murine model of human colitis. In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits mTOR activity in colon cancer cells. In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-γ production but not TNF-α production, indicating preferential inhibitory effects of P2281 on T cell function. In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR. Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis. Given that compounds with anticancer activity show promising anti-inflammatory efficacy, our findings reinforce the cross-therapeutic functionality of potential drugs.Keywords
This publication has 58 references indexed in Scilit:
- Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory TargetScience, 2008
- JAM-A regulates permeability and inflammation in the intestine in vivoJournal of Experimental Medicine, 2007
- Design, Synthesis, and Characterization of Novel Iron Chelators: Structure−Activity Relationships of the 2-Benzoylpyridine Thiosemicarbazone Series and Their 3-Nitrobenzoyl Analogues as Potent Antitumor AgentsJournal of Medicinal Chemistry, 2007
- Acid sphingomyelinase inhibition suppresses lipopolysaccharide‐mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium‐induced colitis in miceImmunology, 2007
- Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodentsBritish Journal of Pharmacology, 2007
- Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitisClinical and Experimental Immunology, 2007
- Targeted Molecular Therapy of the PI3K PathwayAnnals of Surgery, 2006
- The specific JNK inhibitor SP600125 targets tumour necrosis factor‐α production and epithelial cell apoptosis in acute murine colitisImmunology, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporinDigestive Diseases and Sciences, 1993